Literature DB >> 9607023

Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.

K Tochikubo1, M Isaka, Y Yasuda, S Kozuka, K Matano, Y Miura, T Taniguchi.   

Abstract

We examined the mucosal adjuvant activity of recombinant cholera toxin B subunit (rCTB) produced by Bacillus brevis carrying pNU212-CTB by intranasal or oral co-administration of bovine serum albumin (BSA). Intranasal administration stimulated a high level of BSA-specific serum IgG antibody response and BSA-specific IgA antibody responses in the nasal and pulmonary lavages. Oral administration induced a moderate level of BSA-specific serum IgG antibody and a low level of BSA-specific IgA antibody in the large intestinal washes. These results show that CTB alone can act as an intranasal or oral delivery carrier; it also has strong adjuvant properties for stimulating serum IgG and mucosal IgA immune responses to unrelated, non-coupled antigens after intranasal or oral co-immunization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607023     DOI: 10.1016/s0264-410x(97)00194-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Pollen grains for oral vaccination.

Authors:  Shashwati U Atwe; Yunzhe Ma; Harvinder Singh Gill
Journal:  J Control Release       Date:  2014-08-23       Impact factor: 9.776

3.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Olivia Posadas; Jacob A Smith; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

5.  Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.

Authors:  L A Dunn; J A Upcroft; E V Fowler; B S Matthews; P Upcroft
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.

Authors:  Haiyue Xu; Tinashe B Ruwona; Sachin G Thakkar; Yanping Chen; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

7.  Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.

Authors:  Mari Ohmura; Masafumi Yamamoto; Chikako Tomiyama-Miyaji; Yoshikazu Yuki; Yoshifumi Takeda; Hiroshi Kiyono
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

8.  Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations.

Authors:  Mohamed A EL-Malky; Saeed A Al-Harthi; Raafat T Mohamed; Mohamed A EL Bali; Niveen S Saudy
Journal:  Parasitol Res       Date:  2014-04-13       Impact factor: 2.289

9.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice.

Authors:  Xinyuan Qiao; Guiwei Li; Xiangqing Wang; Xiaojing Li; Min Liu; Yijing Li
Journal:  BMC Microbiol       Date:  2009-12-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.